Dr Martens PLC (LSE
OCS) said trading since the start of the financial year has been in line with expectations, with guidance for its current financial year unchanged and profit expected to be weighted to the second half The FTSE 250-listed footwear manufacturer and retailer reported a "positive" performance for its direct-to-consumer business in the Americas, particularly in its shops and full-price sales, though the UK continued to see "a challenging trading backdrop". In Europe, the Middle East and Africa, trading was mixed, while the Asia Pacific region delivered strong growth, led by South Korea.
